TY - JOUR AU - Midha, A. AU - Dearden, S. AU - McCormack, R. PY - 2015 DA - 2015// TI - EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII) JO - Am J Cancer Res VL - 5 ID - Midha2015 ER - TY - JOUR AU - Dearden, S. AU - Stevens, J. AU - Wu, Y. -. L. AU - Blowers, D. PY - 2013 DA - 2013// TI - Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt205 DO - 10.1093/annonc/mdt205 ID - Dearden2013 ER - TY - JOUR AU - Novello, S. AU - Barlesi, F. AU - Califano, R. AU - Cufer, T. AU - Ekman, S. AU - Levra, M. G. AU - Kerr, K. AU - Popat, S. AU - Reck, M. AU - Senan, S. AU - Simo, G. V. AU - Vansteenkiste, J. AU - Peters, S. PY - 2016 DA - 2016// TI - Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw326 DO - 10.1093/annonc/mdw326 ID - Novello2016 ER - TY - JOUR AU - Topalian, S. L. AU - Drake, C. G. AU - Pardoll, D. M. PY - 2015 DA - 2015// TI - Immune checkpoint blockade: a common denominator approach to cancer therapy JO - Cancer Cell VL - 27 UR - https://doi.org/10.1016/j.ccell.2015.03.001 DO - 10.1016/j.ccell.2015.03.001 ID - Topalian2015 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Taube, J. M. AU - Klein, A. AU - Brahmer, J. R. AU - Xu, H. AU - Pan, X. AU - Kim, J. H. PY - 2014 DA - 2014// TI - Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-3271 DO - 10.1158/1078-0432.CCR-13-3271 ID - Taube2014 ER - TY - JOUR AU - Jiang, Y. AU - Li, Y. AU - Zhu, B. PY - 2015 DA - 2015// TI - T-cell exhaustion in the tumor microenvironment JO - Cell Death Dis VL - 6 UR - https://doi.org/10.1038/cddis.2015.162 DO - 10.1038/cddis.2015.162 ID - Jiang2015 ER - TY - JOUR AU - Brahmer, J. AU - Reckamp, K. L. AU - Baas, P. AU - Crinò, L. AU - Eberhardt, W. E. E. AU - Poddubskaya, E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504627 DO - 10.1056/NEJMoa1504627 ID - Brahmer2015 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Herbst, R. S. AU - Baas, P. AU - Kim, D. W. AU - Felip, E. AU - Pérez-Gracia, J. L. AU - Han, J. Y. PY - 2016 DA - 2016// TI - Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)01281-7 DO - 10.1016/S0140-6736(15)01281-7 ID - Herbst2016 ER - TY - JOUR AU - Rittmeyer, A. AU - Barlesi, F. AU - Waterkamp, D. AU - Park, K. AU - Ciardiello, F. AU - Pawel, J. PY - 2017 DA - 2017// TI - Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial JO - Lancet VL - 389 UR - https://doi.org/10.1016/S0140-6736(16)32517-X DO - 10.1016/S0140-6736(16)32517-X ID - Rittmeyer2017 ER - TY - JOUR AU - Pillai, R. N. AU - Behera, M. AU - Owonikoko, T. K. AU - Kamphorst, A. O. AU - Pakkala, S. AU - Belani, C. P. PY - 2016 DA - 2016// TI - Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer JO - J Thorac Oncol VL - 11 ID - Pillai2016 ER - TY - JOUR AU - Gettinger, S. N. AU - Horn, L. AU - Gandhi, L. AU - Spigel, D. R. AU - Antonia, S. J. AU - Rizvi, N. A. PY - 2015 DA - 2015// TI - Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.3708 DO - 10.1200/JCO.2014.58.3708 ID - Gettinger2015 ER - TY - JOUR AU - Reck, M. AU - Rodríguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csőszi, T. AU - Fülöp, A. PY - 2016 DA - 2016// TI - Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1606774 DO - 10.1056/NEJMoa1606774 ID - Reck2016 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. AU - Kvistborg, P. AU - Makarov, V. AU - Havel, J. J. PY - 2015 DA - 2015// TI - Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Brahmer, J. AU - Rodriguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csoszi, T. AU - Fulop, A. PY - 2016 DA - 2016// TI - Health-related quality of life for pembrolizumab vs chemotherapy in advanced NSCLC with PD-L1 TPS ≥50%: data from KEYNOTE-024 JO - J Clin Oncol VL - 34 ID - Brahmer2016 ER - TY - JOUR AU - Scagliotti, G. V. AU - Parikh, P. AU - Pawel, J. AU - Biesma, B. AU - Vansteenkiste, J. AU - Manegold, C. PY - 2008 DA - 2008// TI - Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.0375 DO - 10.1200/JCO.2007.15.0375 ID - Scagliotti2008 ER - TY - JOUR AU - Fukuoka, M. AU - Wu, Y. -. L. AU - Thongprasert, S. AU - Sunpaweravong, P. AU - Leong, S. -. S. AU - Sriuranpong, V. PY - 2011 DA - 2011// TI - Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.4235 DO - 10.1200/JCO.2010.33.4235 ID - Fukuoka2011 ER - TY - JOUR AU - Solomon, B. J. AU - Mok, T. AU - Kim, D. -. W. AU - Wu, Y. -. L. AU - Nakagawa, K. AU - Mekhail, T. PY - 2014 DA - 2014// TI - First-line crizotinib versus chemotherapy in ALK-positive lung cancer JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1408440 DO - 10.1056/NEJMoa1408440 ID - Solomon2014 ER - TY - JOUR AU - Miyauchi, E. AU - Inoue, A. AU - Kobayashi, K. AU - Maemondo, M. AU - Sugawara, S. AU - Oizumi, S. PY - 2015 DA - 2015// TI - Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002) JO - Jpn J Clin Oncol VL - 45 UR - https://doi.org/10.1093/jjco/hyv054 DO - 10.1093/jjco/hyv054 ID - Miyauchi2015 ER - TY - JOUR AU - Rosell, R. AU - Moran, T. AU - Queralt, C. AU - Porta, R. AU - Cardenal, F. AU - Camps, C. PY - 2009 DA - 2009// TI - Screening for epidermal growth factor receptor mutations in lung cancer JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0904554 DO - 10.1056/NEJMoa0904554 ID - Rosell2009 ER - TY - JOUR AU - Goldberg, S. B. AU - Gettinger, S. N. AU - Mahajan, A. AU - Chiang, A. C. AU - Herbst, R. S. AU - Sznol, M. PY - 2016 DA - 2016// TI - Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30053-5 DO - 10.1016/S1470-2045(16)30053-5 ID - Goldberg2016 ER - TY - JOUR AU - Moro-Sibilot, D. AU - Smit, E. AU - de Castro Carpeño, J. AU - Lesniewski-Kmak, K. AU - Aerts, J. G. AU - Villatoro, R. PY - 2015 DA - 2015// TI - Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: analysis from the European FRAME study JO - Lung Cancer VL - 90 UR - https://doi.org/10.1016/j.lungcan.2015.11.011 DO - 10.1016/j.lungcan.2015.11.011 ID - Moro-Sibilot2015 ER - TY - JOUR AU - Peters, S. AU - Bexelius, C. AU - Munk, V. AU - Leighl, N. PY - 2016 DA - 2016// TI - The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer JO - Cancer Treat Rev VL - 45 UR - https://doi.org/10.1016/j.ctrv.2016.03.009 DO - 10.1016/j.ctrv.2016.03.009 ID - Peters2016 ER - TY - JOUR AU - Franceschini, D. AU - Franzese, C. AU - Navarria, P. AU - Ascolese, A. M. AU - Rose, F. AU - Vecchio, M. AU - Santoro, A. AU - Scorsetti, M. PY - 2016 DA - 2016// TI - Radiotherapy and immunotherapy: can this combination change the prognosis of patients with melanoma brain metastases? JO - Cancer Treat Rev VL - 50 UR - https://doi.org/10.1016/j.ctrv.2016.08.003 DO - 10.1016/j.ctrv.2016.08.003 ID - Franceschini2016 ER - TY - JOUR AU - Garon, E. B. AU - Rizvi, N. A. AU - Hui, R. AU - Leighl, N. AU - Balmanoukian, A. S. AU - Eder, J. P. PY - 2015 DA - 2015// TI - Pembrolizumab for the treatment of non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1501824 DO - 10.1056/NEJMoa1501824 ID - Garon2015 ER - TY - JOUR AU - Salloum, R. G. AU - Smith, T. J. AU - Jensen, G. A. AU - Lafata, J. E. PY - 2011 DA - 2011// TI - Using claims-based measures to predict performance status score in patients with lung cancer JO - Cancer VL - 117 UR - https://doi.org/10.1002/cncr.25677 DO - 10.1002/cncr.25677 ID - Salloum2011 ER - TY - JOUR AU - Barlesi, F. AU - Mazieres, J. AU - Merlio, J. P. AU - Debieuvre, D. AU - Mosser, J. AU - Lena, H. PY - 2016 DA - 2016// TI - Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00004-0 DO - 10.1016/S0140-6736(16)00004-0 ID - Barlesi2016 ER - TY - JOUR AU - Khan, S. A. AU - Pruitt, S. L. AU - Xuan, L. AU - Gerber, D. E. PY - 2016 DA - 2016// TI - Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options JO - JAMA Oncol VL - 2 UR - https://doi.org/10.1001/jamaoncol.2016.2238 DO - 10.1001/jamaoncol.2016.2238 ID - Khan2016 ER - TY - STD TI - Socinski M, Creelan B, Horn L, Reck M, Paz-Ares L, Steins M, et al. NSCLC, metastatic CheckMate 026: a phase 3 trial of nivolumab vs investigator’s choice of platinum-based doublet chemotherapy as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. Ann Oncol. 2016;27:LBA7_PR. doi: 10.1093/annonc/mdw435.39. ID - ref31 ER - TY - STD TI - Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2016. Ahead of print. doi:10.1158/1078-0432.CCR-16-1741. ID - ref32 ER - TY - JOUR AU - Gettinger, S. AU - Rizvi, N. A. AU - Chow, L. Q. AU - Borghaei, H. AU - Brahmer, J. AU - Ready, N. PY - 2016 DA - 2016// TI - Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.66.9929 DO - 10.1200/JCO.2016.66.9929 ID - Gettinger2016 ER - TY - JOUR AU - Champiat, S. AU - Ferté, C. AU - Lebel-Binay, S. AU - Eggermont, A. AU - Soria, J. C. PY - 2014 DA - 2014// TI - Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy JO - Oncoimmunology VL - 3 UR - https://doi.org/10.4161/onci.27817 DO - 10.4161/onci.27817 ID - Champiat2014 ER - TY - JOUR AU - Leroi, N. AU - Lallemand, F. AU - Coucke, P. AU - Noel, A. AU - Martinive, P. PY - 2016 DA - 2016// TI - Impacts of ionizing radiation on the different compartments of the tumor microenvironment JO - Front Pharmacol VL - 7 UR - https://doi.org/10.3389/fphar.2016.00078 DO - 10.3389/fphar.2016.00078 ID - Leroi2016 ER - TY - JOUR AU - Liu, W. M. AU - Fowler, D. W. AU - Smith, P. AU - Dalgleish, A. G. PY - 2010 DA - 2010// TI - Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses JO - Br J Cancer VL - 102 UR - https://doi.org/10.1038/sj.bjc.6605465 DO - 10.1038/sj.bjc.6605465 ID - Liu2010 ER - TY - JOUR AU - Peng, J. AU - Hamanishi, J. AU - Matsumura, N. AU - Abiko, K. AU - Murat, K. AU - Baba, T. PY - 2015 DA - 2015// TI - Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-3098 DO - 10.1158/0008-5472.CAN-14-3098 ID - Peng2015 ER - TY - JOUR AU - Zhang, P. AU - Ma, Y. AU - Lv, C. AU - Huang, M. AU - Li, M. AU - Dong, B. PY - 2016 DA - 2016// TI - The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo-adjuvant chemotherapy JO - Cancer Sci VL - 107 UR - https://doi.org/10.1111/cas.13072 DO - 10.1111/cas.13072 ID - Zhang2016 ER - TY - JOUR AU - Langer, C. J. AU - Gadgeel, S. M. AU - Borghaei, H. AU - Papadimitrakopoulou, V. A. AU - Patnaik, A. AU - Powell, S. F. PY - 2016 DA - 2016// TI - Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30498-3 DO - 10.1016/S1470-2045(16)30498-3 ID - Langer2016 ER - TY - JOUR AU - Patel, J. D. AU - Socinski, M. A. AU - Garon, E. B. AU - Reynolds, C. H. AU - Spigel, D. R. AU - Olsen, M. R. PY - 2013 DA - 2013// TI - PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.47.9626 DO - 10.1200/JCO.2012.47.9626 ID - Patel2013 ER - TY - JOUR AU - Curran, M. A. AU - Montalvo, W. AU - Yagita, H. AU - Allison, J. P. PY - 2010 DA - 2010// TI - PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.0915174107 DO - 10.1073/pnas.0915174107 ID - Curran2010 ER - TY - JOUR AU - Hellmann, M. D. AU - Rizvi, N. A. AU - Goldman, J. W. AU - Gettinger, S. N. AU - Borghaei, H. AU - Brahmer, J. R. PY - 2017 DA - 2017// TI - Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(16)30624-6 DO - 10.1016/S1470-2045(16)30624-6 ID - Hellmann2017 ER - TY - JOUR AU - Garon, E. B. AU - Ciuleanu, T. E. AU - Arrieta, O. AU - Prabhash, K. AU - Syrigos, K. N. AU - Goksel, T. PY - 2014 DA - 2014// TI - Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)60845-X DO - 10.1016/S0140-6736(14)60845-X ID - Garon2014 ER - TY - JOUR AU - Reck, M. AU - Kaiser, R. AU - Mellemgaard, A. AU - Douillard, J. -. Y. AU - Orlov, S. AU - Krzakowski, M. PY - 2014 DA - 2014// TI - Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70586-2 DO - 10.1016/S1470-2045(13)70586-2 ID - Reck2014 ER - TY - JOUR AU - Cherny, N. AU - Sullivan, R. AU - Torode, J. AU - Saar, M. AU - Eniu, A. PY - 2016 DA - 2016// TI - ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw213 DO - 10.1093/annonc/mdw213 ID - Cherny2016 ER - TY - JOUR AU - Cherny, N. I. AU - Sullivan, R. AU - Dafni, U. AU - Kerst, J. M. AU - Sobrero, A. AU - Zielinski, C. AU - Vries, E. G. E. AU - Piccart, M. J. PY - 2015 DA - 2015// TI - A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv249 DO - 10.1093/annonc/mdv249 ID - Cherny2015 ER - TY - JOUR AU - Cherny, N. I. AU - Sullivan, R. AU - Dafni, U. AU - Kerst, J. M. AU - Sobrero, A. AU - Zielinski, C. PY - 2016 DA - 2016// TI - ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers JO - ESMO Open VL - 1 UR - https://doi.org/10.1136/esmoopen-2016-000100 DO - 10.1136/esmoopen-2016-000100 ID - Cherny2016 ER -